EHSI · Elite Health Systems Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $1.02M | $0 | $0 | $0 | $1.06M | $3.17M |
| Cost of Revenue | $0 | - | - | - | - | - |
| Gross Profit | $0 | - | - | - | - | - |
| R&D | - | - | - | - | - | - |
| SG&A | $3.96M | $1.79M | $765.0K | $1.39M | $1.06M | $1.20M |
| Total Operating Expenses | - | $1.79M | $765.0K | $1.39M | $1.15M | $1.56M |
| D&A | $6.0K | - | - | - | - | - |
| Operating Income | ($3.84M) | ($1.79M) | ($765.0K) | ($1.39M) | ($89.0K) | $1.61M |
| Interest Expense | - | - | $2.0K | $0 | $3.0K | $25.0K |
| Income Tax | $0 | ($163.0K) | $0 | $39.0K | $120.0K | $323.0K |
| Net Income | ($7.80M) | ($2.06M) | ($816.0K) | ($1.34M) | ($627.0K) | $533.0K |
| EPS - Basic | ($0.35) | ($0.13) | ($0.09) | ($0.17) | $0.07 | - |
| EPS - Diluted | - | - | ($0.17) | ($0.17) | $0.07 | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $3.76M | $4.03M | $466.0K | $1.54M | $2.18M | $2.03M |
| Accounts Receivable | - | - | $0 | $0 | $0 | $346.0K |
| Inventory | - | - | - | - | - | - |
| Accounts Payable | - | - | - | - | - | - |
| Current Assets | $4.48M | $4.25M | $527.0K | $1.55M | $2.24M | $3.01M |
| Total Assets | $6.66M | $4.32M | $1.32M | $1.75M | $3.69M | $4.17M |
| Current Liabilities | $1.34M | $94.0K | $607.0K | $280.0K | $327.0K | $410.0K |
| Long-term Debt | - | - | - | - | - | - |
| Total Liabilities | $1.35M | $143.0K | $676.0K | $291.0K | $361.0K | $487.0K |
| Stockholders' Equity | $5.31M | $4.18M | $645.0K | $1.24M | $2.83M | $3.69M |
| Retained Earnings | ($12.25M) | ($4.45M) | ($2.39M) | ($1.71M) | ($119.0K) | $508.0K |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($2.94M) | ($1.51M) | ($891.0K) | ($1.41M) | $174.0K | $1.12M |
| Investing Cash Flow | ($1.06M) | $263.0K | ($180.0K) | $772.0K | $63.0K | $479.0K |
| Financing Cash Flow | $3.73M | $4.82M | $0 | $0 | ($89.0K) | ($901.0K) |
| CapEx | $0 | - | - | - | - | - |
| Free Cash Flow | ($2.94M) | - | - | - | - | - |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 0.0% | - | - | - | - | - |
| Operating margin | -374.9% | - | - | - | -8.4% | 50.9% |
| EBITDA margin | -374.3% | - | - | - | - | - |
| Net margin | -762.1% | - | - | - | -59.1% | 16.8% |
| Free cash flow margin | -287.1% | - | - | - | - | - |
| FCF / Net income | 0.38 | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - |
| SG&A / Revenue | 386.4% | - | - | - | 100.3% | 37.7% |
| Effective tax rate | - | - | - | - | - | 37.7% |
| Return on assets | -117.1% | -47.6% | -61.8% | -76.5% | -17.0% | 12.8% |
| Return on equity | -146.9% | -49.2% | -126.5% | -107.9% | -22.2% | 14.5% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 3.35 | 45.20 | 0.87 | 5.55 | 6.86 | 7.33 |
| Quick ratio | 3.35 | 45.20 | 0.87 | 5.55 | 6.86 | 7.33 |
| Cash ratio | 2.80 | 42.91 | 0.77 | 5.49 | 6.66 | 4.95 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | - | - | -382.5x | - | -29.7x | 64.6x |
| Equity multiplier | 1.25 | 1.03 | 2.05 | 1.41 | 1.30 | 1.13 |
| Liabilities / Assets | 0.20 | 0.03 | 0.51 | 0.17 | 0.10 | 0.12 |
| Efficiency | ||||||
| Asset turnover | 0.15 | 0.00 | 0.00 | 0.00 | 0.29 | 0.76 |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | 0d | 40d |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | 3.3x | - |
| P / B | - | - | 6.5x | 0.7x | 0.6x | - |
| P / S | - | - | - | - | 1.7x | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | - | - | - | -100.0% | -66.6% | 3.4% |
| Revenue CAGR (3y) | - | - | - | - | -32.3% | - |
| Revenue CAGR (5y) | -20.2% | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | -114.1% | -134.4% | 44.8% | -1457.3% | - | 8.4% |
| Net income growth (YoY) | -279.8% | -151.8% | 39.0% | -113.2% | - | 275.4% |
| EPS growth (YoY) | - | - | 0.0% | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | 27.2% | 547.8% | -47.9% | -56.2% | -23.2% | 16.9% |
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
-1.20
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
2/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- -No share dilution
- -Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Services-Specialty Outpatient Facilities, NEC
Comparing Elite Health Systems Inc. against the 5 most active filers in the same SIC group.